Gilead Sciences, Inc.
NASDAQGILD enters the week with an interesting split: the most consequential recent move came from the Street, not the tape — and it points in a different direction from the broader analyst pack. HSBC raised its price target on Gilead to $175 from $155 last Thursday, while keeping its Buy rating intact. That's the most aggressive target increase in the recent analyst record, and it lands…
A new long-form analysis for GILD this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumGILD enters the week with an interesting split: the most consequential recent move came from the Street, not the tape — and it points in a different direction from the broader analyst pack. HSBC raised its price target…
Snapshot as of 20 Sept 2026
Gilead Sciences enters the post-earnings lull with the stock holding near its highs and the most notable signal coming not from the options market or short sellers, but from the executive suite. CEO Daniel O'Day has…
Gilead Sciences has now printed its Q2 results and the immediate market reaction tells a cleaner story than the analyst community does — the stock jumped 3.1% on August 4 to $135.25, erasing the hesitation that had…
Gilead Sciences reports Q3 results on August 7 having already absorbed one quarterly print — a May release that sent the stock down 3.6% on the day and a further 3.1% over the following week — yet the stock has…
Gilead Sciences reports Q2 results today after the bell with the bullish options fervor from last week fading and the analyst community in a distinctly cautious mood. The options picture has shifted since the prior…
Gilead Sciences heads into its August 4 Q2 print with options traders at their most bullish in a year and the Street sending conflicting signals on valuation. The clearest read this week is in the options market. The…
Gilead Sciences heads into the back half of summer with a notable catalyst in the rearview mirror — a bellwether upgrade that broke a run of analyst caution and helped push the stock to its best weekly gain in…
Gilead Sciences heads into the back half of May nursing a 3.3% weekly decline and a 5.2% one-month loss — a drift that an upgrade this morning from Maxim Group has not been enough to arrest. The freshest piece of…
Gilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April. The…
Gilead Sciences walks into its Q1 2026 results — scheduled for after the close on April 30 — with a notable tension: short interest has risen sharply over the past month, yet the Street remains firmly bullish and a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GILD — free to start on ORTEX.
Sign up for free →Open GILD on ORTEX